Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice
Volta, Mattia , Beccano-Kelly, Dayne , Paschall, Sarah A. , Cataldi, Stefano , MacIsaac, Sarah E, Kuhlmann, Naila , Kadgien, Chelsie , Tatarnikov, Igor , Fox, Jesse D. , Khinda, Jaskaran, Mitchell, Emma , Bergeron, Sabrina , Melrose, Heather L. , Farrer, Matthew J. , Milnerwood, Austen J. , Beccano-Kelly, Dayne A , Melrose, Heather

Mayo Clinic

eLife | September 20, 2017 | Volume: 6 | Issue: No issue available | Pages: No page available

10.7554/elife.28377 | PMID 28930069 Get It

LRRK2 mutations produce end-stage Parkinson’s disease (PD) with reduced nigrostriatal dopamine, whereas, asymptomatic carriers have increased dopamine turnover and altered brain connectivity. LRRK2 pathophysiology remains unclear, but reduced dopamine and mitochondrial abnormalities occur in aged G2019S mutant knock-in (GKI) mice. Conversely, cultured GKI neurons exhibit increased synaptic transmission. We assessed behavior and synaptic glutamate and dopamine function across a range of ages. Young GKI mice exhibit more vertical exploration, elevated glutamate and dopamine transmission, and aberrant D2-receptor responses. These phenomena decline with age, but are stable in littermates. In young GKI mice, dopamine transients are slower, independent of dopamine transporter (DAT), increasing the lifetime of extracellular dopamine. Slowing of dopamine transients is observed with age in littermates, suggesting premature ageing of dopamine synapses in GKI mice. Thus, GKI mice exhibit early, but declining, synaptic and behavioral phenotypes, making them amenable to investigation of early pathophysiological, and later parkinsonian-like, alterations. This model will prove valuable in efforts to develop neuroprotection for PD.
Microdosimetric measurements of a clinical proton beam with micrometer‐sized solid‐state detector
Anderson, Sarah , Tran, Linh T. , Chartier, Lachlan, Petasecca, Marco , Lerch, Michael , Prokopovich, Dale A., Reinhard, Mark I., Perevertaylo, Vladimir L. , Rosenfeld, Anatoly , Herman, Michael , Beltran, Chris , Anderson, Sarah E, Furutani, Keith M. , Herman, Michael G., Rosenfeld, A B , Beltran, Chris J , Anderson, Sarah E.

Mayo Clinic

Medical Physics | September 14, 2017 | Volume: 44 | Issue: 11 | Pages: 6029-6037

10.1002/mp.12583 | PMID 28905399 Get It

PurposeMicrodosimetry is a vital tool for assessing the microscopic patterns of energy deposition by radiation, which ultimately govern biological effect. Solid‐state, silicon‐on‐insulator microdosimeters offer an approach for making microdosimetric measurements with high spatial resolution (on the order of tens of micrometers). These high‐resolution, solid‐state microdosimeters may therefore play a useful role in characterizing proton radiotherapy fields, particularly for making highly resolved measurements within the Bragg peak region. In this work, we obtain microdosimetric measurements with a solid‐state microdosimeter (MicroPlus probe) in a clinical, spot‐scanning proton beam of small spot size.MethodsThe MicroPlus probe had a 3D single sensitive volume on top of silicon oxide. The sensitive volume had an active cross‐sectional area of 250 μm × 10 μm and thickness of 10 μm. The proton facility was a synchrotron‐based, spot‐scanning system with small spot size (σ ≈ 2 mm). We performed measurements with the clinical beam current (≈1 nA) and had no detected pulse pile‐up. Measurements were made in a water‐equivalent phantom in water‐equivalent depth (WED) increments of 0.25 mm or 1.0 mm along pristine Bragg peaks of energies 71.3 MeV and 159.9 MeV, respectively. For each depth, we measured lineal energy distributions and then calculated the dose‐weighted mean lineal energy, . The measurements were repeated for two field sizes: 4 × 4 cm2 and 20 × 20 cm2.ResultsFor both 71.3 MeV and 159.9 MeV and for both field sizes, increased with depth toward the distal edge of the Bragg peak, a result consistent with Monte Carlo calculations and measurements performed elsewhere. For the 71.3 MeV, 4 × 4 cm2 beam (range at 80% distal falloff, R80 = 3.99 cm), we measured keV/μm at WED = 2 cm, and keV/μm at WED = 3.95 cm. For the 71.3 MeV, 20 × 20 cm2 beam, we measured keV/μm at WED = 2.6 cm, and keV/μm at WED = 3 cm. For the 159.9 MeV, 4 × 4 cm2 beam (R80 = 17.7 cm), keV/μm at WED = 5 cm, and keV/μm at WED = 17.6 cm. For the 159.9 MeV, 20 × 20 cm2 beam, keV/μm at WED = 5 cm, and keV/μm at WED = 17.6 cm.ConclusionsWe performed microdosimetric measurements with a novel solid‐state, silicon‐on‐insulator microdosimeter in a clinical spot‐scanning proton beam of small spot size and unmodified beam current. For all of the proton field sizes and energies considered, the measurements of were in agreement with expected trends. Furthermore, we obtained measurements with a spatial resolution of 10 μm in the beam direction. This spatial resolution greatly exceeded that possible with a conventional gaseous tissue‐equivalent proportional counter and allowed us to perform a high‐resolution investigation within the Bragg peak region. The MicroPlus probe is therefore suitable for applications in proton radiotherapy.
Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations
Jakub, James W. , Peled, Anne Warren, Gray, Richard J. , Greenup, Rachel A., Sacchini, Virgilio , McLaughlin, Sarah A. , Tchou, Julia , Vierkant, Robert A. , Jakub, James W , Vierkant, Robert A , Kiluk, John V. , Degnim, Amy C. , Willey, Shawna C.

Mayo Clinic

JAMA Surgery | September 13, 2017 | Volume: 153 | Issue: 2 | Pages: 123

10.1001/jamasurg.2017.3422 | PMID 28903167 Get It

Impact of feedback on adenoma detection rates: Outcomes of quality improvement program
Gurudu, Suryakanth, Boroff, Erika, Atia, Mary A., Umar, Sarah B. , Leighton, Jonathan A. , Faigel, Douglas O. , Ramirez, Francisco C. , Gurudu, Suryakanth R, Boroff, Erika S, Atia, Mary, Crowell, Michael D.

Mayo Clinic

Journal of Gastroenterology and Hepatology | September 11, 2017 | Volume: 33 | Issue: 3 | Pages: 645-649

10.1111/jgh.13984 | PMID 28892839 Get It

AbstractBackground and AimFeedback has been shown to improve performance in colonoscopy including adenoma detection rate (ADR). The frequency at which feedback should be given is unknown. As part of a quality improvement program, we sought to measure the outcome of providing quarterly and monthly feedback on colonoscopy quality measures.MethodsAll screening colonoscopies performed at endoscopy unit at Mayo Clinic Arizona by gastroenterologists between October 2010 and December 2012 were reviewed. Quality indicators, including ADR, were extracted for each individual endoscopist, and feedback was provided. The study period was divided into four distinct groups: pre‐intervention that served as baseline, quarterly feedback, monthly feedback, and post‐intervention. Based on ADR, endoscopists were grouped into “low detectors” (≤ 25%), “average detectors” (26–35%), and “high detectors” (> 35%).ResultsA total of 3420 screening colonoscopies were performed during the study period (555 patients during pre‐intervention, 1209 patients during quarterly feedback, 599 during monthly feedback, and 1057 during the post‐intervention period) by 16 gastroenterologists. The overall ADR for the group improved from 30.5% to 37.7% (P = 0.003). Compared with the pre‐interventional period, all quality indicators measured significantly improved during the monthly feedback and post‐intervention periods but not in the quarterly feedback period.ConclusionsIn our quality improvement program, monthly feedback significantly improved colonoscopy quality measures, including ADR, while quarterly feedback did not. The impact of the intervention was most prominent in the “low detectors” group. Results were durable up to 6 months following the intervention.
C9orf72 poly GA RAN-translated protein plays a key role in amyotrophic lateral sclerosis via aggregation and toxicity
Lee, Youn‐Bok , Baskaran, Pranetha , Gomez-Deza, Jorge, Nishimura, Agnes L. , Smith, Bradley , Troakes, Claire , Adachi, Yoshitsugu, Stepto, Alan, Petrucelli, Leonard , Gallo, Jean‐Marc , Hirth, Frank , Rogelj, Boris , Guthrie, Sarah , Shaw, Christopher E. , Chen, Han-Jou , Troakes, Claire

Mayo Clinic

Human Molecular Genetics | September 11, 2017 | Volume: 26 | Issue: 24 | Pages: 4765-4777

10.1093/hmg/ddx350 | PMID 28973350 Get It

Influence of Inhaled Amiloride on Lung Fluid Clearance in Response to Normobaric Hypoxia in Healthy Individuals
Wheatley, Courtney M. , Baker, Sarah E. , Taylor, Bryan J. , Keller‐Ross, Manda L. , Chase, Steven C. , Carlson, Alex R. , Wentz, Robert J., Snyder, Eric M., Johnson, Bruce D. , Taylor, Bryan J , Keller-Ross, Manda , Baker, Sarah E

Mayo Clinic

High Altitude Medicine & Biology | September 6, 2017 | Volume: 18 | Issue: 4 | Pages: 343-354

10.1089/ham.2017.0032 | PMID 28876128 Get It

A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA -Mutant ER-Positive and HER2-Negative Breast Cancer
Cynthia, X. , Northfelt, Donald W. , Margenthaler, Julie A. , Aft, Rebecca , Gray, Richard J. , Wilke, Lee G. , Haddad, Tufia C. , Moynihan, Timothy J. , Loprinzi, Charles L. , Barnell, Erica K. , Skidmore, Zachary L. , Feng, Yan-Yang, Krysiak, Kilannin , Guo, Zhanfang , Nehring, Leslie, Wisinski, Kari B. , Sanati, Souzan , Al‐Kateb, Hussam , Griffith, Obi L. , Griffith, Malachi , Doyle, L. Austin, Erlichman, Charles , Suman, Vera, Northfelt, Donald, Haddad, Tufia, Moynihan, Timothy, Loprinzi, Charles, Hieken, Tina, Krysiak, Kilannin , Griffith, Malachi , Griffith, Obi L , Suman, Vera J. , Goetz, Matthew P. , Burkard, Mark E. , Ademuyiwa, Foluso O. , Naughton, Michael J. , Tevaarwerk, Amyé , Hieken, Tina J. , Hoog, Jeremy , Mardis, Elaine R. , Hagemann, Ian S. , Vij, Kiran R , Ellis, Matthew J.

Mayo Clinic

Clinical Cancer Research | September 5, 2017 | Volume: 23 | Issue: 22 | Pages: 6823-6832

10.1158/1078-0432.ccr-17-1260 | PMID 28874413 Get It

Abstract Purpose: Hyperactivation of AKT is common and associated with endocrine resistance in estrogen receptor–positive (ER+) breast cancer. The allosteric pan-AKT inhibitor MK-2206 induced apoptosis in PIK3CA-mutant ER+ breast cancer under estrogen-deprived condition in preclinical studies. This neoadjuvant phase II trial was therefore conducted to test the hypothesis that adding MK-2206 to anastrozole induces pathologic complete response (pCR) in PIK3CA mutant ER+ breast cancer. Experimental Design: Potential eligible patients with clinical stage II/III ER+/HER2− breast cancer were preregistered and received anastrozole (goserelin if premenopausal) for 28 days in cycle 0 pending tumor PIK3CA sequencing. Patients positive for PIK3CA mutation in the tumor were eligible to start MK-2206 (150 mg orally weekly, with prophylactic prednisone) on cycle 1 day 2 (C1D2) and to receive a maximum of four 28-day cycles of combination therapy before surgery. Serial biopsies were collected at preregistration, C1D1 and C1D17. Results: Fifty-one patients preregistered and 16 of 22 with PIK3CA-mutant tumors received study drug. Three patients went off study due to C1D17 Ki67 >10% (n = 2) and toxicity (n = 1). Thirteen patients completed neoadjuvant therapy followed by surgery. No pCRs were observed. Rash was common. MK-2206 did not further suppress cell proliferation and did not induce apoptosis on C1D17 biopsies. Although AKT phosphorylation was reduced, PRAS40 phosphorylation at C1D17 after MK-2206 persisted. One patient acquired an ESR1 mutation at surgery. Conclusions: MK-2206 is unlikely to add to the efficacy of anastrozole alone in PIK3CA-mutant ER+ breast cancer and should not be studied further in the target patient population. Clin Cancer Res; 23(22); 6823–32. ©2017 AACR.
Triheptanoin versus trioctanoin for long‐chain fatty acid oxidation disorders: a double blinded, randomized controlled trial
Gillingham, Melanie B. , Martin, Julie , Rose, Sarah, Goldstein, Amy , El‐Gharbawy, Areeg , DeWard, Stephanie J. , Lasarev, Michael , Pollaro, Jim, DeLany, James P. , Burchill, Luke J. , Shoemaker, James D. , Matern, Dietrich , Heitner, Stephen B. , Goodpaster, Bret H. , Harding, Cary O. , Vockley, Jerry , Burchill, Luke J , Gillingham, Melanie B

Mayo Clinic

Journal of Inherited Metabolic Disease | September 4, 2017 | Volume: 40 | Issue: 6 | Pages: 831-843

10.1007/s10545-017-0085-8 | PMID 28871440 Get It

AbstractBackgroundObservational reports suggest that supplementation that increases citric acid cycle intermediates via anaplerosis may have therapeutic advantages over traditional medium‐chain triglyceride (MCT) treatment of long‐chain fatty acid oxidation disorders (LC‐FAODs) but controlled trials have not been reported. The goal of our study was to compare the effects of triheptanoin (C7), an anaplerotic seven‐carbon fatty acid triglyceride, to trioctanoin (C8), an eight‐carbon fatty acid triglyceride, in patients with LC‐FAODs.MethodsA double blinded, randomized controlled trial of 32 subjects with LC‐FAODs (carnitine palmitoyltransferase‐2, very long‐chain acylCoA dehydrogenase, trifunctional protein or long‐chain 3‐hydroxy acylCoA dehydrogenase deficiencies) who were randomly assigned a diet containing 20% of their total daily energy from either C7 or C8 for 4 months was conducted. Primary outcomes included changes in total energy expenditure (TEE), cardiac function by echocardiogram, exercise tolerance, and phosphocreatine recovery following acute exercise. Secondary outcomes included body composition, blood biomarkers, and adverse events, including incidence of rhabdomyolysis.ResultsPatients in the C7 group increased left ventricular (LV) ejection fraction by 7.4% (p = 0.046) while experiencing a 20% (p = 0.041) decrease in LV wall mass on their resting echocardiogram. They also required a lower heart rate for the same amount of work during a moderate‐intensity exercise stress test when compared to patients taking C8. There was no difference in TEE, phosphocreatine recovery, body composition, incidence of rhabdomyolysis, or any secondary outcome measures between the groups.ConclusionsC7 improved LV ejection fraction and reduced LV mass at rest, as well as lowering heart rate during exercise among patients with LC‐FAODs.Clinical Trial Registration: Clinicaltrials.gov NCT01379625.
Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells
Gil, Małgorzata , Salisbury, Jeffrey L., Goetz, Mathew P., Haddad, Tufia C. , Iankov, Ianko, Kurokawa, Chenye B., Shumacher, Nicole, D’Assoro, Antonino B. , Suman, Vera, Degnim, Amy, Haddad, Tufia, Ingle, James N. , Galanis, Evanthia , D'Assoro, Antonino B, Opyrchal, Mateusz , Goetz, MP, Suman, Vera J. , Degnim, Amy C. , McCubrey, James Andrew

Mayo Clinic

Oncotarget | September 2, 2017 | Volume: 8 | Issue: 53 | Pages: 91803-91816

10.18632/oncotarget.20610 | PMID 29207686 Get It

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer
Northfelt, Don W., Mahr, Michael A. , Ralya, Andrew T., Kuffel, Mary J., Buhrow, Sarah A. , Safgren, Stephanie L. , McGovern, Renee M., Black, John L. , Dockter, Travis , Haddad, Tufia C. , Erlichman, Charles , Adjei, Alex A. , Visscher, Dan W., Kipp, Benjamin R. , Liu, Minetta C. , Hawse, John R. , Doroshow, James H. , Collins, Jerry M. , Streicher, Howard , Ames, Matthew M. , Élez, Elena , Reid, Joel M. , Kuffel, Mary, Black, John, Haddad, Tufia, Visscher, Dan, Chalmers, Zachary R, Frampton, Garrett, Ingle, James N. , Safgren, Stephanie L , Goetz, Matthew P. , Suman, Vera J. , Chalmers, Zachary Rockow , Frampton, Garrett M. , Elez, Elena

Mayo Clinic

Journal of Clinical Oncology | August 30, 2017 | Volume: 35 | Issue: 30 | Pages: 3391-3400

10.1200/jco.2017.73.3246 | PMID 28854070 Get It

Purpose Endoxifen is a tamoxifen metabolite with potent antiestrogenic activity. Patients and Methods We performed a phase I study of oral Z-endoxifen to determine its toxicities, maximum tolerated dose (MTD), pharmacokinetics, and clinical activity. Eligibility included endocrine-refractory, estrogen receptor–positive metastatic breast cancer. An accelerated titration schedule was applied until moderate or dose-limiting toxicity occurred, followed by a 3+3 design and expansion at 40, 80, and 100 mg per day. Tumor DNA from serum (circulating cell free [cf); all patients] and biopsies [160 mg/day and expansion]) was sequenced. Results Of 41 enrolled patients, 38 were evaluable for MTD determination. Prior endocrine regimens during which progression occurred included aromatase inhibitor (n = 36), fulvestrant (n = 21), and tamoxifen (n = 15). Patients received endoxifen once daily at seven dose levels (20 to 160 mg). Dose escalation ceased at 160 mg per day given lack of MTD and endoxifen concentrations > 1,900 ng/mL. Endoxifen clearance was unaffected by CYP2D6 genotype. One patient (60 mg) had cycle 1 dose-limiting toxicity (pulmonary embolus). Overall clinical benefit rate (stable > 6 months [n = 7] or partial response by RECIST criteria [n = 3]) was 26.3% (95% CI, 13.4% to 43.1%) including prior tamoxifen progression (n = 3). cfDNA mutations were observed in 13 patients ( PIK3CA [n = 8], ESR1 [n = 5], TP53 [n = 4], and AKT [n = 1]) with shorter progression-free survival ( v those without cfDNA mutations; median, 61 v 132 days; log-rank P = .046). Clinical benefit was observed in those with ESR1 amplification (tumor; 80 mg/day) and ESR1 mutation (cfDNA; 160 mg/day). Comparing tumor biopsies and cfDNA, some mutations ( PIK3CA, TP53, and AKT) were undetected by cfDNA, whereas cfDNA mutations ( ESR1, TP53, and AKT) were undetected by biopsy. Conclusion In endocrine-refractory metastatic breast cancer, Z-endoxifen provides substantial drug exposure unaffected by CYP2D6 metabolism, acceptable toxicity, and promising antitumor activity.